コンテンツへスキップ
Merck

In utero diagnosis of long QT syndrome by magnetocardiography.

Circulation (2013-11-13)
Bettina F Cuneo, Janette F Strasburger, Suhong Yu, Hitoshi Horigome, Takayoshi Hosono, Akihiko Kandori, Ronald T Wakai
要旨

The electrophysiology of long QT syndrome (LQTS) in utero is virtually unstudied. Our goal here was to evaluate the efficacy of fetal magnetocardiography (fMCG) for diagnosis and prognosis of fetuses at risk of LQTS. We reviewed the pre/postnatal medical records of 30 fetuses referred for fMCG because of a family history of LQTS (n=17); neonatal/childhood sudden cardiac death (n=3), or presentation of prenatal LQTS rhythms (n=12): 2° atrioventricular block, ventricular tachycardia, heart rate < 3(rd) percentile. We evaluated heart rate and reactivity, cardiac time intervals, T-wave characteristics, and initiation/termination of Torsade de Pointes, and compared these with neonatal ECG findings. After birth, subjects were tested for LQTS mutations. Based on accepted clinical criteria, 21 subjects (70%; 9 KCNQ1, 5 KCNH2, 2 SCN5A, 2 other, 3 untested) had LQTS. Using a threshold of corrected QT= 490 ms, fMCG accurately identified LQTS fetuses with 89% (24/27) sensitivity and 89% (8/9) specificity in 36 sessions. Four fetuses (2 KCNH2 and 2 SCN5A), all with corrected QT ≥ 620 ms, had frequent episodes of Torsade de Pointes, which were present 22-79% of the time. Although some episodes initiated with a long-short sequence, most initiations showed QRS aberrancy and a notable lack of pause dependency. T-wave alternans was strongly associated with severe LQTS phenotype. Corrected QT prolongation (≥490 ms) assessed by fMCG accurately identified LQTS in utero; extreme corrected QT prolongation (≥620 ms) predicted Torsade de Pointes. FMCG can play a critical role in the diagnosis and management of fetuses at risk of LQTS.

材料
製品番号
ブランド
製品内容

Sigma-Aldrich
リドカイン, powder
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
リドカイン 塩酸塩 一水和物, solid
カタログ番号
容量
在庫状況
単価
数量
Sigma-Aldrich
リドカイン, analytical standard
カタログ番号
容量
在庫状況
単価
数量
Supelco
Lidocaine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
カタログ番号
容量
在庫状況
単価
数量
Supelco
塩酸リドカイン, Pharmaceutical Secondary Standard; Certified Reference Material
カタログ番号
容量
在庫状況
単価
数量
Supelco
リドカイン, Pharmaceutical Secondary Standard; Certified Reference Material
カタログ番号
容量
在庫状況
単価
数量
リドカイン 塩酸塩 一水和物, European Pharmacopoeia (EP) Reference Standard
カタログ番号
容量
在庫状況
単価
数量
リドカイン, European Pharmacopoeia (EP) Reference Standard
カタログ番号
容量
在庫状況
単価
数量